Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

learn more

See Our Portfolio

$1.8 billion in assets, with a track record of investing and returning capital since 2000.

learn more

Latest News

U.S. FDA Approves Supplemental New Drug Application (sNDA) For ERLEADA® (Apalutamide) For The Treatment Of Patients With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

September 17, 2019
HORSHAM, Pa., Sept. 17, 2019 -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved ERLEADA® (apalutamide) for the…
READ MORE

Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2)

September 16, 2019
WAYNE, Pa., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced positive results from its Phase…
READ MORE

Alexion And Bridgebio Announce Japanese License Agreement For Eidos’ Transthyretin Amyloidosis (ATTR) Investigational Medicine

September 9, 2019
BOSTON & SAN FRANCISCO--(BUSINESS WIRE)--Sep. 9, 2019-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and BridgeBio Pharma, Inc.’s (NASDAQ:BBIO) subsidiary Eidos Therapeutics, Inc. (NASDAQ:EIDX) today announced an agreement that grants Alexion an exclusive…
READ MORE